ArticleDigestive diseases and sciences2025
Combination of Frailty and Sarcopenia Predicts Peri-operative Outcomes in Patients Undergoing Liver Transplantation: Analysis of the National Inpatient Sample.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis.Hepatobiliary surgery and nutrition · 2026Article
- Beyond Identification: Operationalizing Frailty and Sarcopenia Assessment for Pre-transplant Optimization.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcopenia and frailty contribute to adverse clinical outcomes in patients with cirrhosis awaiting and after liver transplantation (LT). However, the impact of sarcopenia/physical frailty on perioperative LT outcomes has not been reported. The effect of physical frailty and sarcopenia on hospitalization outcomes in patients undergoing liver transplantation was evaluated in a nationwide dataset.
methodsAdult patients undergoing liver transplantation from 2016 to 2020 in the National Inpatient Sample database without/with frailty (defined by the hospital frailty risk score) and/or sarcopenia (defined by muscle-loss phenotype) were analyzed. Patients were stratified into those without sarcopenia or frailty (sarcopenia/frailty), with either sarcopenia/frailty, and those with both sarcopenia and frailty. Univariate and multivariate logistic/linear regression analyses were performed to compare in-hospital mortality, perioperative organ system complications, length of stay, and costs during the LT hospitalization in patients without/with frailty and/or sarcopenia. Adjustments were made for patient demographics, hospital characteristics, modified Charlson comorbidity index, etiology, and decompensation of liver disease.
resultsAmong the 34,405 LT recipients, there was a high prevalence of frailty alone (35%), sarcopenia alone (7.6%), or both sarcopenia/frailty (29.2%). Patients with both frailty and sarcopenia had higher in-hospital mortality (4.6%), periprocedural complications (79.4%), and non-routine discharge (71.4%) than patients with frailty, sarcopenia alone or neither sarcopenia nor frailty. Combined frailty and sarcopenia was associated with higher odds of in-hospital mortality, compared to patients with neither sarcopenia or frailty (aOR 4.06, p < 0.001).
conclusionsCombined frailty and sarcopenia are associated with an increased risk of mortality in hospitalized patients undergoing LT. Increased awareness and interventions to improve these risk factors should be emphasized before LT.
Indexed as
Identifiers
40748517What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.